[go: up one dir, main page]

WO2011028794A3 - Treatment of huntington's disease with cycloserine and an nmda receptor antagonist - Google Patents

Treatment of huntington's disease with cycloserine and an nmda receptor antagonist Download PDF

Info

Publication number
WO2011028794A3
WO2011028794A3 PCT/US2010/047520 US2010047520W WO2011028794A3 WO 2011028794 A3 WO2011028794 A3 WO 2011028794A3 US 2010047520 W US2010047520 W US 2010047520W WO 2011028794 A3 WO2011028794 A3 WO 2011028794A3
Authority
WO
WIPO (PCT)
Prior art keywords
cycloserine
disease
huntington
receptor antagonist
nmda receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/047520
Other languages
French (fr)
Other versions
WO2011028794A2 (en
Inventor
Jay S. Schneider
John P. Rodzvilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAZARUS THERAPEUTICS Inc
Original Assignee
LAZARUS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAZARUS THERAPEUTICS Inc filed Critical LAZARUS THERAPEUTICS Inc
Publication of WO2011028794A2 publication Critical patent/WO2011028794A2/en
Publication of WO2011028794A3 publication Critical patent/WO2011028794A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treating or preventing Huntington's disease in a human patient in need thereof comprising co-administering D-cycloserine and an NMDA receptor antagonist or sigma receptor agonist to said patient.
PCT/US2010/047520 2009-09-01 2010-09-01 Treatment of huntington's disease with cycloserine and an nmda receptor antagonist Ceased WO2011028794A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23871209P 2009-09-01 2009-09-01
US61/238,712 2009-09-01

Publications (2)

Publication Number Publication Date
WO2011028794A2 WO2011028794A2 (en) 2011-03-10
WO2011028794A3 true WO2011028794A3 (en) 2011-07-21

Family

ID=43649941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/047520 Ceased WO2011028794A2 (en) 2009-09-01 2010-09-01 Treatment of huntington's disease with cycloserine and an nmda receptor antagonist

Country Status (1)

Country Link
WO (1) WO2011028794A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764702C2 (en) * 2014-10-07 2022-01-19 Сейдж Терапьютикс, Инк. Neuroactive compounds and their application methods

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105246486B (en) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 neuroactive steroids
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX2021005052A (en) 2015-07-06 2022-10-11 Sage Therapeutics Inc Oxysterols and methods of use thereof.
HUE053778T2 (en) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA44526A (en) 2016-04-01 2021-06-02 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (en) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of NMDA-related conditions
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
MA46565A (en) 2016-10-18 2019-08-28 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
CN119350419A (en) 2016-10-18 2025-01-24 萨奇治疗股份有限公司 Oxysterols and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157926A1 (en) * 2003-02-06 2004-08-12 Uriel Heresco-Levy Pharmaceutical compositions for the treatment of movement disorders
US20060142241A1 (en) * 2004-11-01 2006-06-29 Yoo Seo H Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
WO2007006157A1 (en) * 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
WO2008034815A1 (en) * 2006-09-19 2008-03-27 Laboratorios Del Dr. Esteve, S.A. Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157926A1 (en) * 2003-02-06 2004-08-12 Uriel Heresco-Levy Pharmaceutical compositions for the treatment of movement disorders
US20060142241A1 (en) * 2004-11-01 2006-06-29 Yoo Seo H Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
WO2007006157A1 (en) * 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
WO2008034815A1 (en) * 2006-09-19 2008-03-27 Laboratorios Del Dr. Esteve, S.A. Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764702C2 (en) * 2014-10-07 2022-01-19 Сейдж Терапьютикс, Инк. Neuroactive compounds and their application methods

Also Published As

Publication number Publication date
WO2011028794A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2011028794A3 (en) Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
IL217901B (en) Use of an amount of laquninimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a human subject suffering from a bdnf-related disease
EP1988852A4 (en) Methods and devices for delivery of prosthetic heart valves and other prosthetics
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
MX354210B (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
PL2262476T3 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
IL194820A0 (en) Devices and methods for treatment of tissue
PH12013500892B1 (en) Composition for use in the prevention and\or treatment of skin conditions and skin diseases
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
MY173215A (en) Acetylcysteine compositions and methods of use thereof
WO2011109433A9 (en) Tissue for prosthetic implants and grafts, and methods associated therewith
IL216967B (en) 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases
GB201008885D0 (en) Methods for administration and formulations for the treatment of reginal adipose tissue
WO2011146926A3 (en) Systems and methods for treatment of sleep apnea
GB201108964D0 (en) Medicament and method of diagnosis
WO2011044523A3 (en) Compositions and methods for treating obesity
ZA201007005B (en) Methods of diagnosing, preventing and treating bone mass diseases
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
EP2517704A4 (en) Pharmaceutical composition for treating parkinson's disease and preparation method thereof
UA64530U (en) method for treating hyperesthesia of solid teeth tissues in patients with gastroesofageal reflux disease
WO2009029762A3 (en) Farnesylamine inhibitors of the visual cycle
TW200738229A (en) Memantine for the normalization of visual acuity deficits
UA39741U (en) Technique for drainage after thyroid surgery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814422

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10814422

Country of ref document: EP

Kind code of ref document: A2